RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
Recalls & Warnings June 20, 2003 FTC Charges Marketers of Seasilver with False and Deceptive Claims On June 19, 2003, The Federal Trade Commission (FTC) and the Food and Drug Administration (FDA) announced coordinated actions against two companies - both charged with promoting the dietary supplement "Seasilver" with unsubstantiated medical claims
[DOI] [PubMed] [Google Scholar] 26.Filli L, Schwab ME
Elliemd, as a complex formulation, requires a different qualification approach
Wound healing involves the production of TGF-1, fibronectin, VEGF, and collagen-I
First-line treatment for NAFLD is lifestyle modification to achieve weight reduction, particularly through diet and exercise [6]
